Middle East Pharmaceutical Industries Co. (AVALON PHARMA) - Mubasher Info
KSA
Mubasher TV
 Contact Us Advertising   العربية
KSA
TDWL Closed
24 July 10:29 AM

Middle East Pharmaceutical Industries Co. (4016)

Last update: 23 July 03:11 PM market time.
59.80
-0.20
-0.33%
Open 59.90
Previous Close 60.00
High 60.60
Low 59.60
Stock Statistics
Volume 38,361
Turnover 2,304,416.10
All data are 15 minutes late during market session
This mark means that there are news on this date.

Stock

Par Value 10.0 Saudi Riyal
Market Cap 1,196,000,000.00 Saudi Riyal
Book Value (BVPS) 20.87 Saudi Riyal Based on: First Quarter 2026
P/B Ratio 4.68 Last update: 2026-06-05
EPS 5.38 Saudi Riyal Based on: First Quarter 2026
P/E Ratio 20.09 Last update: 2026-06-05
Trading Currency Saudi Riyal

Company Statistics

Current Total Shares 20,000,000
Company Capital 200,000,000.00

News

Photo Archive
Avalon Pharma appoints new leadership team Company News
Photo Archive
CMA greenlights Avalon Pharma’s capital hike Corporate Actions
Photo Archive
Avalon Pharma, Bio-Thera reach license agreements for BAT3306 in MENA Global Economy
Photo Archive
Avalon Pharma unveils SAR 25m cash dividends for H2-24 Cash Dividends
Photo Archive
Avalon Pharma’s board approves dividends for H1-24 Cash Dividends
Photo Archive
Avalon Pharma obtains SAR 70m from Emirates NBD Banking and Finance
More

Market Announcements

31 May 03:45 PM
Middle East Pharmaceutical Industries Co. announces the deposit of the amounts from selling the shares fractions resulted from the company’s capital Increase in the eligible shareholder’s accounts
14 May 08:28 AM
The Securities Depository Center Company (Edaa) Announces Implementing a Corporate Action on Middle East Pharmaceutical Industries Co. Securities
12 May 08:45 AM
The Saudi Exchange announces that the fluctuation limits for Middle East Pharmaceutical Industries Co. will be based on a share price of ^58.85
12 May 08:30 AM
Middle East Pharmaceutical Industries Co. Announces the Results of the Extraordinary General Assembly’s Meeting Included the Approval of the Company’s Capital Increase. (First Meeting)
More